氨酸配方可以防止异二醇诱导的心脏缩
Zhong-Yan Zhou1, Jie Ma2, Wai-Rong Zhao3
1Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China; Department of Pharmacology and Pharmacy, The University of Hong Kong, Hong Kong Special Administrative Regions of China; State Key Laboratory of Pharmaceutical Biotechnology, The University of Hong Kong, Hong Kong Special Administrative Regions of China.
概括
传统中医药中的"清氨酸" (QXY) 通过减少心脏缩来预防心力衰竭. 像psoralen (PRN) 和kaempferol (KMP) 这样的关键活性成分通过阻断流入和改善线粒体功能来起作用.
科学领域:
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
- 传统中国医药 传统中国医药
背景情况:
- 心力衰竭是一种严重的疾病,以心脏缩,炎症和纤维化为特征.
- 传统中医药 (TCM) 配方青素 (QXY) 在治疗心力衰竭方面表现出有效性,但其机制尚不清楚.
研究的目的:
- 为了确定QXY的活性成分.
- 阐明QXY保护心脏缩的机制.
主要方法:
- 使用斑马鱼模型来评估QXY对异二醇 (ISO) 诱导的心脏缩的保护作用.
- 在QXY中确定了八种化合物,包括psoralen (PRN),kaempferol (KMP) 和icariin (ICA).
- 研究了QXY对H9c2心肌细胞的影响,重点关注流入,线粒体功能和细胞信号通路.
主要成果:
- 在斑马鱼中,QXY显著改善了ISO诱导的心脏缩和功能障碍.
- 在斑马鱼中,PRN,KMP和ICA证明了对心脏缩的保护作用.
- QXY抑制了的流入,降低了MDA水平,增强了ATP的产生,并改善了心肌细胞中的线粒体膜潜力.
- QXY抑制了心肌细胞缩和细胞骨重组,同时调节了SMAD2,MYPT1和MLC酸化.
结论:
- 松烯 (PRN),甲费醇 (KMP) 和伊卡林 (ICA) 被确定为QXY的主要活性成分.
- QXY的心脏保护作用源于阻断的流入,缓解线粒体功能障碍,并防止细胞骨重组.
- 这些发现为QXY治疗心力衰竭的治疗潜力提供了机械洞察力.
相关概念视频
01:26Heart Failure Drugs: Inotropic Agents
570
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
570
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
421
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
421
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
972
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
972
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
738
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
738
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.4K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.4K
01:22Heart Failure Drugs: Diuretics
363
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
363